Bio-Rad Laboratories (NYSE:BIO) EVP Sells $539,882.00 in Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP James Barry sold 1,400 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $385.63, for a total value of $539,882.00. Following the sale, the executive vice president directly owned 625 shares in the company, valued at $241,018.75. This trade represents a 69.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO traded down $10.24 during midday trading on Thursday, reaching $375.75. 24,590 shares of the stock traded hands, compared to its average volume of 305,521. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.18 and a quick ratio of 2.37. The stock has a market capitalization of $10.05 billion, a PE ratio of 9.89 and a beta of 1.06. Bio-Rad Laboratories, Inc. has a one year low of $236.73 and a one year high of $396.23. The company’s 50 day moving average is $373.82 and its 200 day moving average is $316.75.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Wednesday, November 4th. The medical research company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.23 by $0.42. The company had revenue of $656.40 million for the quarter, compared to analysts’ expectations of $649.94 million. Bio-Rad Laboratories had a net margin of 39.45% and a return on equity of 3.58%. Bio-Rad Laboratories’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.26 earnings per share. On average, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.71 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on BIO shares. Weiss Ratings upgraded shares of Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Citigroup increased their price target on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Wells Fargo & Company lifted their price target on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada boosted their price objective on Bio-Rad Laboratories from $390.00 to $440.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $366.67.

Institutional Investors Weigh In On Bio-Rad Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its holdings in shares of Bio-Rad Laboratories by 6.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 648 shares of the medical research company’s stock worth $245,000 after acquiring an additional 39 shares during the last quarter. Cetera Investment Advisers grew its holdings in Bio-Rad Laboratories by 0.6% during the 1st quarter. Cetera Investment Advisers now owns 7,596 shares of the medical research company’s stock valued at $2,117,000 after purchasing an additional 48 shares during the last quarter. Rehmann Capital Advisory Group raised its position in Bio-Rad Laboratories by 8.3% in the 2nd quarter. Rehmann Capital Advisory Group now owns 954 shares of the medical research company’s stock worth $280,000 after purchasing an additional 73 shares during the period. Hantz Financial Services Inc. raised its position in Bio-Rad Laboratories by 7.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,142 shares of the medical research company’s stock worth $431,000 after purchasing an additional 81 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its position in Bio-Rad Laboratories by 2.3% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 3,808 shares of the medical research company’s stock worth $1,438,000 after purchasing an additional 86 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.